Axenoll
A high-resolution 3D screen printing and bioprinting technology company that designs, develops, and manufactures advanced solutions for medical, life science, and cosmetic applications using gentle additive manufacturing processes.
- CEO / Founder
- Lutz Freiwald
- Team Size
- 10-50
- Stage
- Commercial
- Total Funding
- $8.26M
- Latest Round
- Venture Round
- Key Investors
- Xlife Sciences AG
Technology & Products
Key Products
["Patient-specific bioactive/resorbable implants","Multifunctional wound dressings with drug release","3D multilayer microfluidic chips and Lab-on-a-Chip systems","Bioprinting platforms with living cells for tissue models","Cell scaffolds for tissue engineering","Personalized cosmetic facial masks and skincare products","Drug delivery systems (transdermal, mucosal, targeted)","Organ-on-a-Chip systems for drug testing","Smart textiles with integrated sensors","Surgical guides and biocompatible sensor carriers"]
Technological Advantage
Modular system architecture enables uncomplicated upscaling for mass customization. Technology offers parallel processing of various geometries in single runs, low-temperature processing for sensitive materials, and combination of fine-to-coarse structures. Provides complete service from feasibility studies through R&D, prototyping, and serial production under GMP/sterile conditions. In-house capabilities include paste formulation, screen design, process optimization, and quality management. Offers flexible business models including contract manufacturing, technology transfer, and licensing.
Differentiation
Value Proposition
Enables reproducible, scalable production of complex 3D structures with exceptional material flexibility including living cells, under GMP and sterile conditions. Offers complete development-to-manufacturing pipeline with ability to print diverse materials (polymers, biomaterials, ceramics, metals) and combine synthetic with biological components seamlessly.
How They Differentiate
Exclusive global license for Exentis 3D Mass Customization® technology enabling high-resolution 3D screen printing of cellular/molecular materials under GMP conditions; unique capability to process living cells while maintaining viability through gentle low-temperature processing; complete end-to-end service from R&D to serial production
Market & Competition
Target Customers
Medical device manufacturers, pharmaceutical companies, biotechnology firms, cosmetics companies, research institutions, and organizations requiring custom bioprinting, microfluidic devices, or specialized medical products
Industry Verticals
["Medical Technology","Pharmaceuticals","Life Sciences","Biotechnology","Cosmetics","Microfluidics","Regenerative Medicine","Wearables & Smart Textiles"]
Competitors
BICO Group AB (CELLINK); 3D Systems Corporation; Aspect Biosystems
Growth & Milestones
Growth Metrics
€9M balance sheet total (2023); 10-50 employees; established commercial operations with serial production capabilities
Major Milestones
["Exclusive global licensing agreement for Exentis 3D Mass Customization® technology","Strategically significant patent granted by European Patent Office for biological tissue generation process (Jan 2023)","$8.26M venture capital investment secured (Jul 2021)","Established GMP-compliant manufacturing capabilities","Multiple R&D projects funded by German and Swiss research programs"]
Notable Customers
Medical device manufacturers; Pharmaceutical companies; Biotechnology firms; Research institutions